KR101925436B1 - 암 치료를 위한 종양 저 산소 상태의 유도 - Google Patents

암 치료를 위한 종양 저 산소 상태의 유도 Download PDF

Info

Publication number
KR101925436B1
KR101925436B1 KR1020107025113A KR20107025113A KR101925436B1 KR 101925436 B1 KR101925436 B1 KR 101925436B1 KR 1020107025113 A KR1020107025113 A KR 1020107025113A KR 20107025113 A KR20107025113 A KR 20107025113A KR 101925436 B1 KR101925436 B1 KR 101925436B1
Authority
KR
South Korea
Prior art keywords
tumor
stilbene
tyrapazamin
low oxygen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107025113A
Other languages
English (en)
Korean (ko)
Other versions
KR20110050583A (ko
Inventor
루이 민 리
펙-선 린
Original Assignee
버지니아 커먼웰스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버지니아 커먼웰스 유니버시티 filed Critical 버지니아 커먼웰스 유니버시티
Publication of KR20110050583A publication Critical patent/KR20110050583A/ko
Application granted granted Critical
Publication of KR101925436B1 publication Critical patent/KR101925436B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020107025113A 2008-04-10 2009-04-08 암 치료를 위한 종양 저 산소 상태의 유도 Active KR101925436B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4396408P 2008-04-10 2008-04-10
US61/043,964 2008-04-10
PCT/US2009/039899 WO2009126705A2 (en) 2008-04-10 2009-04-08 Induction of tumor hypoxia for cancer therapy

Publications (2)

Publication Number Publication Date
KR20110050583A KR20110050583A (ko) 2011-05-16
KR101925436B1 true KR101925436B1 (ko) 2018-12-05

Family

ID=41162569

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025113A Active KR101925436B1 (ko) 2008-04-10 2009-04-08 암 치료를 위한 종양 저 산소 상태의 유도

Country Status (6)

Country Link
US (4) US8591921B2 (enExample)
JP (2) JP5731372B2 (enExample)
KR (1) KR101925436B1 (enExample)
CN (2) CN104043125B (enExample)
TW (1) TWI504391B (enExample)
WO (1) WO2009126705A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2592103Y2 (ja) 1992-07-23 1999-03-17 東海旅客鉄道株式会社 ケーブルトラフ
CA2613312C (en) 2005-06-29 2014-10-14 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
WO2009126705A2 (en) 2008-04-10 2009-10-15 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
EP3311835B1 (en) * 2010-07-12 2021-03-24 Threshold Pharmaceuticals Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
WO2012145684A1 (en) 2011-04-22 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Transient hypoxia inducers and their use
US9254299B2 (en) 2011-12-22 2016-02-09 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
CN102512692B (zh) * 2012-01-16 2014-07-16 北京大学 肿瘤靶向栓塞治疗组合物及其制备方法
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
CA2930001A1 (en) * 2013-11-11 2015-05-14 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US9586056B2 (en) * 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
ES2822557T3 (es) * 2014-08-08 2021-05-04 Poseida Therapeutics Inc Composiciones y su uso para inducir la embolización microvascular de tumores mediada por nanopartículas
EP3250215B1 (en) 2015-01-29 2025-04-09 Oxyrase, Inc. Methods for inhibiting tumor growth
US20180127748A1 (en) * 2015-05-15 2018-05-10 The General Hospital Corporation Methods relating to the prevention and treatment of drug resistance
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
IL309273A (en) * 2015-10-21 2024-02-01 Teclison Ltd Compositions and methods for immune-mediated cancer therapy
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
WO2017197342A1 (en) * 2016-05-13 2017-11-16 Teclison Limited Methods for treating liver tissue
CN107007571B (zh) * 2017-02-24 2020-08-21 福州市传染病医院 肿瘤微酸性敏感的铜-药物共配位自组装纳米粒及应用
CN110051848A (zh) * 2019-05-06 2019-07-26 中国科学院长春应用化学研究所 药物组合、应用以及抗肿瘤的药物
CN110585214A (zh) * 2019-09-25 2019-12-20 湖北大学 一种促进治疗肿瘤效果的纳米粒子及其合成方法
CN110713596B (zh) * 2019-11-08 2022-04-29 西北师范大学 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统
JP7730130B2 (ja) * 2021-03-02 2025-08-27 ドリームメディカルパートナーズ株式会社 塞栓材及びその製造方法
WO2023049207A1 (en) * 2021-09-22 2023-03-30 The University Of Texas System Quantitative magnetic resonance imaging and tumor forecasting
CN114344482B (zh) * 2022-01-14 2023-05-12 重庆医科大学附属第二医院 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用
WO2024006901A1 (en) * 2022-06-29 2024-01-04 Diffusion Pharmaceuticals Llc Uses of bipolar trans carotenoids in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087026A2 (en) 2005-12-23 2007-08-02 Amgen Inc. Solid-state form of amg 706 and pharmaceutical compositions thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5616584A (en) 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
PT1155689E (pt) 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
GB9404400D0 (en) 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
DE69835824T2 (de) 1997-03-07 2007-03-29 Sanofi-Aventis U.S. Llc Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
JP2005504070A (ja) * 2001-09-13 2005-02-10 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー 化学塞栓用油性パクリタキセル組成物及び処方物並びにその製造方法
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
JP2006519209A (ja) * 2003-02-26 2006-08-24 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ ネモルビシン（ｎｅｍｏｒｕｂｉｃｉｎ）の肝臓内投与により肝臓癌を治療するための方法
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
WO2009126705A2 (en) 2008-04-10 2009-10-15 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087026A2 (en) 2005-12-23 2007-08-02 Amgen Inc. Solid-state form of amg 706 and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
US20140065139A1 (en) 2014-03-06
US10426779B2 (en) 2019-10-01
KR20110050583A (ko) 2011-05-16
JP2015110602A (ja) 2015-06-18
WO2009126705A3 (en) 2010-02-18
US20120087913A1 (en) 2012-04-12
CN102026634B (zh) 2014-01-22
US8591921B2 (en) 2013-11-26
JP5944018B2 (ja) 2016-07-05
WO2009126705A8 (en) 2011-04-14
TW201002312A (en) 2010-01-16
US20170224693A1 (en) 2017-08-10
CN104043125B (zh) 2018-01-12
HK1202057A1 (en) 2015-09-18
TWI504391B (zh) 2015-10-21
WO2009126705A2 (en) 2009-10-15
JP2011516565A (ja) 2011-05-26
CN102026634A (zh) 2011-04-20
US9649316B2 (en) 2017-05-16
JP5731372B2 (ja) 2015-06-10
US10159676B2 (en) 2018-12-25
CN104043125A (zh) 2014-09-17
US20180050039A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
KR101925436B1 (ko) 암 치료를 위한 종양 저 산소 상태의 유도
Zhao et al. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy
Ning et al. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials
Kotagiri et al. Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer
Li et al. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade
Huang et al. Photodynamic therapy synergizes with irinotecan to overcome compensatory mechanisms and improve treatment outcomes in pancreatic cancer
Miller et al. Poly (ethylene glycol)–paclitaxel–alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases
JP2000510460A (ja) スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
US10278954B2 (en) Method of treating a CNS disorder using a water-soluble histone deacetylase inhibitor
Wang et al. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer
EP2965757A1 (en) Pharmaceutical compositions for treating malignant glioma
Garona et al. Addition of vasopressin synthetic analogue [V4Q5] dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
Joo et al. Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor
Han et al. A PDGFRβ-targeting nanodrill system for pancreatic fibrosis therapy
JP6608431B2 (ja) 脳腫瘍に対するｓｎ−３８装填ミセルのｃｅｄ
CN112961082A (zh) 一种血管阻断剂与双载药仿生脂质体联用的给药系统
Dickson et al. Interferon β–mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model
EP2152236B1 (en) Pharmaceutical composition of an anthracycline
KR20090021211A (ko) 약물 투여 방법
HK1202057B (en) Induction of tumor hypoxia for cancer therapy
JP4020256B2 (ja) 前立腺癌の局所治療剤
JP2011079788A (ja) 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
US20210252151A1 (en) Method for optical opening of the blood-brain barrier
Chen Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140331

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151007

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160205

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151007

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20160511

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20160205

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20170424

Appeal identifier: 2016101002781

Request date: 20160511

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20160524

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20160511

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20160107

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20140331

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2016101002781; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160511

Effective date: 20170424

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20170424

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20160511

Decision date: 20170424

Appeal identifier: 2016101002781

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2017201003522; APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20170424

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20180629

Appeal identifier: 2017201003522

Request date: 20170524

PJ1302 Judgment (patent court)

Patent event date: 20180629

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20170524

Decision date: 20180629

Appeal identifier: 2017201003522

Appeal kind category: Appeal against decision to decline refusal

PJ2201 Remand (intellectual property tribunal)

Patent event code: PJ22012S01I

Comment text: Written Judgment (Patent Court)

Patent event date: 20180724

Request date: 20180724

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2018131000022

Decision date: 20180823

J301 Trial decision

Free format text: TRIAL NUMBER: 2018131000022; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20180724

Effective date: 20180823

PJ1301 Trial decision

Patent event code: PJ13011S09D

Patent event date: 20180823

Comment text: Trial Decision on Final Judgment on Revocation

Appeal kind category: Appeal against decision to decline refusal

Request date: 20180724

Decision date: 20180823

Appeal identifier: 2018131000022

PS0901 Examination by remand of revocation
S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20180829

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20180823

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20181129

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20181130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211110

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20221109

Start annual number: 5

End annual number: 5